@article{5668c46987704dd6b73fb2fcf5d90b15,
title = "Reducing fungal exposure critical for treating rhinosinusitis with or without polyps [Response to letter]",
author = "Claus Bachert and Neil Bhattacharyya and Martin Desrosiers and Khan, {Asif H.}",
note = "Funding Information: Dr Martin Desrosiers reports personal fees from GlaxoSmithKline, grants from Sanofi and Regeneron, advisory board, speaker bureau, and clinical investigator for GlaxoSmithKline, Sanofi and Regeneron, and AstraZeneca, during the conduct of the study; is a major equity holder of Probionase Therapies outside the submitted work; has received clinical trial funding from AstraZeneca, GlaxoSmithKline, Probionase Therapies, and Sanofi; and is an advisory board member of Regeneron Pharmaceuticals, Inc. and Sanofi. Funding Information: Medical writing/editorial assistance was provided by Matt Lewis, PhD of Adelphi Group, Macclesfield, UK, in accordance with Good Publication Practice (GPP3) guidelines and funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.",
year = "2021",
doi = "10.2147/JAA.S314846",
language = "English",
volume = "14",
pages = "393--395",
journal = "Journal of Asthma and Allergy",
issn = "1178-6965",
}